Cryoport (CYRX) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$186.5M

Revenue (quarter)

$49.0M

Revenue growth (year over year)

+7.74%

Gross profit (trailing twelve months)

$87.8M

Gross margin

47.08%

Net income (trailing twelve months)

−$37.4M

Net income (quarter)

−$8.3M

Net income growth (year over year)

−107.58%

Net margin

−20.05%

Return on equity

−9.02%

EPS (trailing twelve months)

−$0.90

Book value per share

$8.77

P/E (trailing twelve months)

—

Price to book

1.75

Debt to assets

35.11%

Payout ratio

—

Dividend yield

—

Company profile

CryoPort Inc is a provider of integrated, temperature-controlled supply chain solutions for the life sciences industry, with a focus on supporting the cell and gene therapy market. The company provides services such as temperature-controlled logistics, biostorage, bioservices, cryopreservation solutions, and cryogenic systems manufacturing. It operates through two reportable segments: Life Sciences Services and Life Sciences Products. It generates the majority of its revenue from the Life Sciences Services segment.

• Is Cryoport (CYRX) profitable?

  No. Cryoport reported a net loss of $37.4M over the trailing twelve months.

• How much revenue does Cryoport (CYRX) make?

  Cryoport generated $186.5M in revenue over the trailing twelve months, up 7.74% year over year.

• How do I buy stock in Cryoport (CYRX)?

  CYRX trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.